Key Takeaways
- Revenue up 38% YoY, but organic story is softer: Consolidated growth was acquisition-driven; standalone grew 11.3% YoY as one large client destocked and the organic order book declined.
- Margins fell on one-off costs and a large-deal drag: Adjusted EBITDA margin dropped 109 bps YoY to 8.1%, hit by M&A integration fees, a credit-loss provision, and a low-margin program that management says ramps down significantly in Q4.
- Altek is the quarter's structural win: The U.S.-based acquisition closed, integration is on plan, and management sees a clear line of sight to 10% sustainable EBITDA margins, with upside from "Made in U.S." policy tailwinds.
- The pipeline is large but lumpy: Over $1 billion in B2B opportunities and three large deals in advanced negotiation, yet conversion timelines remain uncertain and the organic backlog is being consumed faster than it is replenished.
- What to watch next quarter: Whether the large margin-drag deal actually ramps down and lifts Q4 margins as promised, whether the destocking client resumes orders, and whether any of the three advanced-stage large deals convert to backlog.
Altek Acquisition & the U.S. Manufacturing Bet
- First consolidated quarter: Altek Electronics is now fully included in results, shifting the industry mix heavily toward industrial (up 47% YoY) and MedTech (up 156% YoY), and pushing the Rest of World geography share to 61%.
- Integration progressing to plan: Go-to-market teams across both businesses are now jointly planning and executing with top key clients; financial integration is complete and supply-chain synergy mapping is underway across components, distribution and overall spend.
- "Made in U.S." tailwind: Management sees Altek as a direct beneficiary of Trump administration industrial policy and localization requirements, giving the company U.S. manufacturing capability for defense customers who require U.S.-made equipment.
- Margin profile: Altek's EBITDA margin was similar to Cyient DLM standalone this quarter; historical performance is ~10%, and post-acquisition integration expenses are expected to fade, with a clear line of sight to 10% sustainable. Management calls 10% a milestone, not a ceiling.
- Strategic differentiation: The combined entity can now offer safety-critical, highly reliable, highly complex engineering-centric electronics manufacturing from both India and the U.S., a capability management believes is rare at its scale.
Bodanapu: "We are one of the few, if not one of the only one EMS company in the world that has this capability, especially at our scale, which is essentially to do safety critical, highly reliable, highly complex engineering centric electronics from India, from the U.S."
Margin Walk & the Q4 Recovery Promise
- What compressed margins: Adjusted EBITDA margin fell 109 bps YoY to 8.1%. The three main drags were ~₹8 crore of one-off M&A integration costs (banker and lawyer fees), an expected credit loss provision on domestic receivables that aged during the December holiday quarter, and one large low-margin deal.
- The ECL provision is a timing item: Other expenses rose because receivables moved right during the holidays, triggering a conservative provision. Management says the probability of reversal next quarter is extremely high and declined to quantify the amount separately.
- The large-deal drag ends in Q4: One large program that has been a slight margin headwind is expected to ramp down significantly in Q4, which management says will drive substantial margin improvement in the quarter and argue well for the next financial year.
- Full-year margin flat: Management expects the full-year margin to be closer to flat year-on-year, with the exit quarter providing the first demonstration of improvement.
- 10% is the first milestone: The stated aspiration is to consistently deliver 10% EBITDA margin and then grow from there; management says the aspiration is bigger than 10%.
Kulkarni: "As we get into Q4, I think the one large deal, which is slightly a drag on the margins, is going to ramp down significantly, right? And therefore, I think our margins will improve in Q4 and beyond. So, you will see substantial improvement in the margins for the Q4 quarter."
Organic Demand & the Order Book
- Standalone growth slowed: Standalone revenue grew 11.3% YoY, held back by one top key client that had built inventory and reduced demand; that client's demand is expected to return in coming quarters.
- Organic backlog declined: The organic order book shrank because consumption from a large customer outpaced new order wins. Management attributes the gap to timing shifts in awards for larger, longer-term programs rather than any specific competitive or pricing trend.
- A&D clients are a mixed picture: The top 3–4 aero/defense clients have a strong favorable outlook, but below that tier, feedback is mixed with some softness in industrial and medical segments.
- Sector margins are similar: Management stated that A&D, Medical and Industrial deliver very similar profit margins; variability is client-specific or program-specific, not sector-specific.
- New logos continue: The company secured one leading global technology company in energy services/solutions plus at least six new logos of similar scale as earlier quarters.
The Pipeline: Large but Unconverted
- Over $1 billion in B2B opportunities: The pipeline includes specific large opportunities in advanced stages of negotiation, with more updates expected in coming quarters.
- Three large deals in advanced negotiation: These are predominantly rest-of-world opportunities; domestic opportunities are also being worked but were not highlighted as standout large deals this quarter. Management declined to provide a ballpark quantum or specific conversion milestones.
- Aircraft tooling contract not yet in backlog: A large OEM award announced November 6 carries a high total contract value but has no specific purchase orders yet and is not counted in the current order book.
- Conversion takes time: New awards typically take 9–12 months to reach meaningful revenue, and the three large deals being discussed are expected to impact FY26 and the next two fiscal years, with variability in the speed of conversion depending on transfer programs and other factors.
- Honeywell order undisclosed: Management declined to provide specifics on the $550 million, 15-year strategic opportunity, citing client confidentiality.
Balance Sheet & Working Capital
- DSO improved: Days sales outstanding fell both QoQ and YoY to 76 days; management is targeting a range of 60–70 days.
- Net working capital improved to 120 days: Free cash flow was positive, with the 7-day release translating to a meaningful number that also included Altek cash generation.
- DIO remains elevated at 129 days: This is higher than desired; management has a roadmap to bring it down to 90–100 days.
- Customer advances declining: Advances dropped to ~16 days as existing advances were consumed; no new advances are expected in the near term.
- IPO proceeds nearly deployed: ~₹190 crore used by year-end, with ~₹100 crore left for next FY for working capital. No substantial CAPEX expansion is needed; enough capacity exists for the next year with only incremental additions during the year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q4 margin improvement | Substantial margin improvement as large low-margin deal ramps down significantly | Q4 FY25 |
| ECL provision reversal | Conservative credit-loss provision on domestic receivables to reverse upon collection | Next quarter (Q4 FY25) |
| Full-year margin | Closer to flat year-on-year | FY25 |
| Altek sustainable EBITDA margin | Clear line of sight to 10% | Sustainable basis (no date) |
| DIO target | Reduce from 129 days to 90–100 days | Roadmap (no date) |
| DSO target | Reduce to 60–70 days from 76 days | No date |
| 30% CAGR | Healthy number for mid-to-long term, but not a firm year-on-year guide; variability expected | Mid-to-long term |
| Large deal conversion | Three advanced-stage deals expected to impact FY26 and next two fiscal years; dependent on transfer programs | FY26 and beyond |
| Client inventory recovery | Demand from the destocking client expected to return | Coming quarters |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue (consolidated) | ₹444.2 cr, +38.4% YoY, includes Altek |
| Revenue (standalone) | ₹357.3 cr, +11.3% YoY |
| Adjusted EBITDA | ₹35.9 cr, margin 8.1%, lower by 109 bps YoY |
| Reported EBITDA | ~₹27.9 cr, ~₹8 cr lower than adjusted due to one-off M&A expenses |
| Adjusted PAT | ₹16.6 cr, margin 3.7%, de-growth of ~10% YoY |
| Reported PAT | ₹10.8 cr, after adjusting for M&A expenses |
| Order backlog (consolidated) | ₹2,142.9 cr, includes Altek backlog of ₹291.5 cr |
| Order backlog (standalone) | ~₹1,850 cr |
| Industrial revenue growth | +47% YoY |
| Medical revenue growth | +156% YoY |
| Box build growth | +16% YoY |
| DSO | 76 days, improved QoQ and YoY |
| DIO | 129 days, elevated; target 90–100 days |
| Net working capital | ~120 days, improved from 127 days QoQ |
| Free cash flow | ₹47.8 cr, positive for the quarter |
| Geography mix (Rest of world) | 61%, post-Altek consolidation |
| Geography mix (India) | 39%, post-Altek consolidation |
| Altek EBITDA margin (annual basis) | ~10%, comparable to Cyient DLM at EBITDA level |
| Additional amortization from Altek acquisition | ~$1 mn per year |
| M&A one-off expenses | ₹8 cr, booked as exceptional item |
| IPO proceeds utilized | ₹135 cr so far; ~₹190 cr expected by year-end |
| Order backlog execution timeline | 18–24 months |
| New award to meaningful revenue timeline | 9–12 months |